CA3110520A1 - Thyroid hormone receptor beta agonist compounds - Google Patents
Thyroid hormone receptor beta agonist compounds Download PDFInfo
- Publication number
- CA3110520A1 CA3110520A1 CA3110520A CA3110520A CA3110520A1 CA 3110520 A1 CA3110520 A1 CA 3110520A1 CA 3110520 A CA3110520 A CA 3110520A CA 3110520 A CA3110520 A CA 3110520A CA 3110520 A1 CA3110520 A1 CA 3110520A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- compound
- alkyl
- methyl
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722312P | 2018-08-24 | 2018-08-24 | |
| US62/722,312 | 2018-08-24 | ||
| US201962867117P | 2019-06-26 | 2019-06-26 | |
| US62/867,117 | 2019-06-26 | ||
| PCT/US2019/047968 WO2020041741A1 (en) | 2018-08-24 | 2019-08-23 | Thyroid hormone receptor beta agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3110520A1 true CA3110520A1 (en) | 2020-02-27 |
Family
ID=69584321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3110520A Pending CA3110520A1 (en) | 2018-08-24 | 2019-08-23 | Thyroid hormone receptor beta agonist compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10800767B2 (enExample) |
| EP (2) | EP4755882A3 (enExample) |
| JP (3) | JP7579253B2 (enExample) |
| CN (2) | CN122562793A (enExample) |
| AU (2) | AU2019325656B2 (enExample) |
| CA (1) | CA3110520A1 (enExample) |
| DK (1) | DK3840755T3 (enExample) |
| ES (1) | ES3070127T3 (enExample) |
| MA (1) | MA53448A (enExample) |
| TW (1) | TWI837169B (enExample) |
| WO (1) | WO2020041741A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| WO2020228577A1 (zh) * | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) * | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| JP2023537271A (ja) | 2020-07-24 | 2023-08-31 | イニファーム，インク． | チオフェンｈｓｄ１７ｂ１３阻害剤とその使用 |
| CN114437034A (zh) * | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| CN116670118B (zh) | 2020-11-13 | 2026-02-06 | 伊尼制药公司 | 二氯苯酚hsd17b13抑制剂及其用途 |
| CN114621207B (zh) * | 2020-12-11 | 2025-02-11 | 广东东阳光药业股份有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| JP2024510935A (ja) * | 2021-03-03 | 2024-03-12 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
| US20240239761A1 (en) * | 2021-03-19 | 2024-07-18 | Medshine Discovery Inc. | Bicyclic phenol compounds and use thereof |
| CN116940566A (zh) * | 2021-03-19 | 2023-10-24 | 南京明德新药研发有限公司 | 双环吡啶酮类化合物及其应用 |
| US12617772B2 (en) | 2021-04-05 | 2026-05-05 | Inipharm, Inc. | Hydroxypyridine HSD17B13 inhibitors and uses thereof |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| CN116554063B (zh) * | 2023-05-23 | 2025-03-07 | 江苏省农用激素工程技术研究中心有限公司 | 氟胺磺隆中间体的制备方法 |
| WO2026092583A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2473162A1 (en) * | 2002-01-30 | 2003-08-07 | Kissei Pharmaceutical Co., Ltd. | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| US7572799B2 (en) * | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| GB0327319D0 (en) * | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| ATE480524T1 (de) * | 2005-07-21 | 2010-09-15 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten |
| WO2007132475A1 (en) | 2006-05-15 | 2007-11-22 | Cadila Healthcare Limited | Selective tr-beta 1 agonist |
| WO2008130637A1 (en) * | 2007-04-18 | 2008-10-30 | New York University | Hydrazide compounds as thyroid hormone receptor modulators and uses thereof |
| TWI698430B (zh) * | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| CN109574995B (zh) | 2018-01-23 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| CN119552152A (zh) | 2018-10-12 | 2025-03-04 | 益方生物科技(上海)股份有限公司 | 甲状腺激素受体激动剂 |
-
2019
- 2019-08-23 WO PCT/US2019/047968 patent/WO2020041741A1/en not_active Ceased
- 2019-08-23 MA MA053448A patent/MA53448A/fr unknown
- 2019-08-23 CN CN202610545235.1A patent/CN122562793A/zh active Pending
- 2019-08-23 DK DK19852050.4T patent/DK3840755T3/da active
- 2019-08-23 EP EP26158747.1A patent/EP4755882A3/en active Pending
- 2019-08-23 AU AU2019325656A patent/AU2019325656B2/en active Active
- 2019-08-23 US US16/549,979 patent/US10800767B2/en active Active
- 2019-08-23 ES ES19852050T patent/ES3070127T3/es active Active
- 2019-08-23 JP JP2021533405A patent/JP7579253B2/ja active Active
- 2019-08-23 TW TW108130298A patent/TWI837169B/zh active
- 2019-08-23 EP EP19852050.4A patent/EP3840755B1/en active Active
- 2019-08-23 CA CA3110520A patent/CA3110520A1/en active Pending
- 2019-08-23 CN CN201980066702.0A patent/CN112805005B/zh active Active
-
2024
- 2024-08-29 US US18/818,705 patent/US20250236615A1/en active Pending
- 2024-10-25 JP JP2024187991A patent/JP7846735B2/ja active Active
-
2025
- 2025-07-22 AU AU2025206402A patent/AU2025206402A1/en active Pending
-
2026
- 2026-04-03 JP JP2026061675A patent/JP2026117048A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020041741A1 (en) | 2020-02-27 |
| US20200062742A1 (en) | 2020-02-27 |
| JP2021535207A (ja) | 2021-12-16 |
| JP2026117048A (ja) | 2026-07-14 |
| JP7579253B2 (ja) | 2024-11-07 |
| EP3840755B1 (en) | 2026-02-18 |
| DK3840755T3 (da) | 2026-05-11 |
| TWI837169B (zh) | 2024-04-01 |
| ES3070127T3 (en) | 2026-06-12 |
| CN112805005B (zh) | 2026-05-12 |
| EP3840755A4 (en) | 2022-04-20 |
| US20250236615A1 (en) | 2025-07-24 |
| AU2019325656A1 (en) | 2021-03-11 |
| JP7846735B2 (ja) | 2026-04-15 |
| EP4755882A3 (en) | 2026-08-05 |
| EP4755882A2 (en) | 2026-06-10 |
| EP3840755A1 (en) | 2021-06-30 |
| TW202023560A (zh) | 2020-07-01 |
| MA53448A (fr) | 2022-04-20 |
| US10800767B2 (en) | 2020-10-13 |
| CN112805005A (zh) | 2021-05-14 |
| AU2019325656B2 (en) | 2025-04-24 |
| AU2025206402A1 (en) | 2025-08-07 |
| JP2025020206A (ja) | 2025-02-12 |
| CN122562793A (zh) | 2026-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7846735B2 (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| JP7624025B2 (ja) | アミノ酸化合物および使用方法 | |
| JP7646632B2 (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| CN112839655B (zh) | 甲状腺激素受体β促效剂化合物 | |
| CA3212130A1 (en) | Thyroid hormone receptor beta agonist compounds | |
| EP4482579B1 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| HK40037094A (en) | Amino acid compounds and methods of use | |
| HK40037094B (en) | Amino acid compounds and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240726 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240730 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240730 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240730 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241219 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250210 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250210 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250410 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250729 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250808 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250815 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250922 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250922 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D141 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CONDITIONAL ALLOWANCE Effective date: 20260611 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260611 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260729 |